Conference Description

June 21, 2008
Hyatt Regency Columbus
350 N. High Street
Columbus, OH

Tell a friend about this conference

Download the brochure for this conference

Expiration Date: June 21, 2008

Estimated Time To Complete CME Activity: 7.0 Hours

Medium/Method: Live Conference

Hardware/Software Requirements: None

CME Credits: 13.75*

Nonrefundable registration fee: $0.

Target Audience: Physicians, Nurse Practitioners, and Physician Assistants.

Program Summary:

This educational activity is designed to provide primary care physicians, nurse practitioners, physician assistants and other primary care providers the opportunity to learn about Restless Leg Syndrome, Insomnia, Incretins and Incretin-Mimetics and Insulin Therapy in Diabetes, TIA and CVA risk reduction and prevention, Chronic Pain Management, Fibromyalgia, and Rheumatoid Arthritis.

In planning this CME activity, the National Association for Continuing Education (NACE) performed a needs assessment. A literature search was conducted, national guidelines were reviewed, survey data was analyzed, and experts in each therapeutic area were consulted to determine gaps in practitioner knowledge, competence or performance. Learning objectives (see below), linked to identified gaps, were developed and will be addressed by each presenter.

This multidisciplinary program will utilize a variety of educational techniques incorporating the various aspects of Adult Learning Principles. There will be emphasis on audience participation utilizing interactive case-based presentations to deliver educational material. Participants will be asked to engage in pre and post testing to collect data for outcome studies and to uncover unmet needs for future programming.

Each participant will be provided with a syllabus containing presentations, clinical tools, and practical guidelines at the start of the program to be used for future reference.

At the conclusion of this program, participants should be able to:

1. list the four cardinal features of RLS; Name the category of pharmaceutical agents which is first line treatment for RLS; Define and treat augmentation
2. Recognize the significant impact of insomnia in patients with co-morbid conditions; Increase awareness of behavioral and cognitive therapies; More effectively incorporate appropriate pharmacotherapeutic manage ment to decrease morbidity and enhance quality of life
3. discuss new treatments for type 2 Diabetes including incretin-mimetics, DPP-IV inhibitors, and incretin analogs; Compare and contrast newer therapies with traditional antidiabetic agents; Discuss the place of newer agents in the overall management strategy for patients with Diabetes
4. explain the natural progression to relative insulin deficiency in patients with type 2 Diabetes; Recognize when to initiate insulin therapy and how to overcome barriers to do so; Identify methods of optimizing glycemic control in patients with type 2 Diabetes with the use of insulin; Explain risks and discuss approaches for minimizing risk of hypoglycemia and weight gain
5. more readily identify an acute ischemic stroke; Utilize current management strategies to improve outcomes; Recognize the most effective treatments for secondary prevention
6. Develop a practical approach to office management of the chronic pain patient; Define such terms as addiction, physical dependence, tolerance, and iatrogenic addiction; Understand the difference between a chronic pain patient and a patient with the disease of addiction; Understand federal law for prescribing opioids; Choose appropriate opioids for the treatment of chronic pain
7. recognize criteria for accurate diagnosis of fibromyalgia established by the American College of Rheumatology; Describe patient demographics and associated features in fibromyalgia; Describe differential diagnosis and basic testing to aid in excluding other conditions; Understand the role of non-pharmacologic and pharma cologic treatment options; Recognize the role of analgesics like tramadol, and non-opioid pain modulating agents such as pramipexole, pregabalin, and duloxetine; Describe emerging therapeutic options on the horizon for fibromyalgia
8. define criteria for the diagnosis of RA; Outline potential benefits of early diagnosis and aggressive management; Describe why the TNF inhibitors and newer biologics can potentially improve outcomes and summarize their efficacy and safety

Agenda

7:15-7:45 am		Continental Breakfast and Registration
7:45-8:00		Welcome Remarks Jack Kravitz, MD
8:00-9:00		Restless Leg Syndrome: Optimizing Treatment from a Patient Centered Approach Phyllis Zee, MD, PhD
9:00-9:50		Chronic Insomnia in Co-Morbid States Phyllis Zee, MD, PhD
9:50-10:10		Break/Vendor Area
10:10-11:00		Incretins and Incretin-Mimetics: The Role in Diabetes Robert Tanenberg, MD
11:00-12:00		Diabetes Mellitus – Case Studies in Insulin Therapy Robert Tanenberg, MD
12:00-1:00		Lunch
1:00-2:00		TIA and CVA - Risk Reduction and Prevention Michael Sloan, MD
2:00-3:00		The Truth About Opiois Pain Management Howard Heit, MD
3:00-3:20		Break
3:20-4:10		Understanding Fibromyalgia – Biology and Therapy Jefrey Lieberman, MD
4:10-5:00		Rheumatoid Arthritis – Early Diagnosis and Effective Management Jefrey Lieberman, MD

Faculty

Howard A. Heit, MD, FACP, FASAM
Certified in Addiction Medicine and as
a Medical Review Officer Chronic Pain Specialist
Assistant Clinical Professor, Georgetown University

Jefrey Lieberman, MD, FACP
Medical Director, Arthritis Care Center, Dekalb Medical Center
Clinical Associate, Emory University College of Medicine
Atlanta, GA

Michael Allan Sloan, MD
Professor and Director
TGH/USF Stroke Program
Department of Neurology University of South Florida College of Medicine
Tampa, FL

Robert J. Tanenberg, MD, FACP
Professor of Medicine, Division of Endocrinology
Director, Diabetes Fellowship
Brody School of Medicine
Director, Diabetes and Obesity Center
East Carolina University
Greenville, NC

Phyllis C. Zee, MD, PhD
Professor of Neurology and Neurobiology and Physiology
Northwestern University
Chicago, IL

Program Chair
Gregg Sherman, MD

Activity Director
Michelle Frisch, MPH

This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Massachusetts Medical School (UMMS) and the National Association for Continuing Education. The University of Massachusetts Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The University of Massachusetts Medical School designates this educational activity for a maximum of 7.5 AMA PRA Category I Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Under the auspices of the University of Massachusetts Medical School Office of Continuing Education this offering meets the requirements for 8.8 contact hours, as specified by the Massachusetts Board of Registration in Nursing (244-CMR 5.04). Each nurse should claim only those hours of credit that he/she actually spend in the educational activity.

Policy on Faculty and Provider Disclosure: It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

This activity is supported by educational donations provided by: Amgen and Wyeth Pharmaceuticals, Amylin, Bayer HealthCare, Boehringer Ingelheim, Bristol-Myers Squibb, Endo, Lilly, Novo nordisk, sanofi-aventis, Sepracor, UCB.